Saturday, 31 October 2026European Markets

FIN.OUEST AFRICAIN Stock Was 9.37% Up On Wednesday

Loading stream...

(vianews) - the market ended the session with fin.ouest africain (foaf.pa) jumping 9.37% to €42.00 on wednesday while cac 40 fell 0.46% to €7,234.25.

about fin.ouest africain

fin.ouest africain provides various financial services. it offers car, personal, business risk, transportation, and other property and casualty insurance products; and life insurance products for individuals, private and public companies, and organizations. it also invests in bonds and shares in listed and unlisted companies; and provides wealth management services, including building and managing real estate assets. the company was founded in 1951 and is based in dakar, senegal.

volatility

fin.ouest africain's last week, last month's, and last quarter's current intraday variation average was 20.36%, 15.86%, and 17.54%.

fin.ouest africain's highest amplitude of average volatility was 20.36% (last week), 17.64% (last month), and 17.54% (last quarter).

volume

today's last reported volume for fin.ouest africain is 696 which is 340.5% above its average volume of 158.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, fin.ouest africain's stock is considered to be oversold (<=20).

more news about fin.ouest africain (foaf.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com